Navigation Links
Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System

BASKING RIDGE, N.J., Aug. 24 /PRNewswire/ -- Regado Biosciences, Inc, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced enrollment of the first patient in the first Phase I study of a subcutaneous administration formulation of the REG1 anticoagulation system. The study is a double-blind, randomized, placebo-controlled, single ascending dose study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of RB006 administered subcutaneously, with and without intravenously administered RB007, in healthy adult volunteers. REG1 is a two component system composed of RB006, a specific and direct inhibitor of Factor IXa, and RB007, the specific controlling agent that reverses RB006. To date, this will be the first known use of an aptamer in humans delivered by the subcutaneous route of administration. Recently, Regado successfully completed a phase 2a study of intravenously administered REG1 in stable coronary artery disease patients undergoing elective PCI.

This Phase 1 study will have three primary objectives. First, it will determine the pharmacokinetics, bioavailability and pharmacodynamics of subcutaneous administered RB006. Second, it will determine the safety and tolerability of subcutaneous administered RB006 and third, it will determine the impact of intravenous administered RB007 on the pharmacokinetics, bioavailability and pharmacodynamics in subjects who received subcutaneous administered RB006. The study will enroll a total of 32 subjects.

Dr. Steven L. Zelenkofske, Chief Medical Officer of Regado Biosciences stated, "This is an important milestone in expanding the possible applications of the REG1 system." David J. Mazzo, PhD., President and CEO of Regado Biosciences, added, "The introduction of subcutaneously administered REG1 promises to bring an unprecedented level of individual specific control and flexibility to the physician caring for patients in need of chronic anticoagulant therapy."

About Regado Biosciences, Inc.

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

More information can be found at

SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences Expands Medical Advisory Board
2. Regado Biosciences Establishes Medical Advisory Board
3. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
4. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
7. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
8. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
9. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
10. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
11. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
Post Your Comments:
(Date:10/12/2017)... ... 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK Business ... US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants module ... and biologic sealants used in surgical applications. BioMedGPS estimates the market will grow ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Personal eye wash is a basic first aid ... at a time. So which eye do you rinse first if a dangerous substance enters ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its dirt ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):